Presentation (CTI)

OBJECTIVES: European systems use out-of-pocket (OOP) caps and early/temporary access financing to mitigate financial toxicity, support timely access to medicines, and protect payer budgets.
METHODS: Targeted desk research identified national policies limiting maximum annual OOP exposure for medicines and the main design features of early/temporary access financing. Data was extracted from official payer/agency sources and supplemented with published cross-country policy literature.
RESULTS: OOP protection is common but heterogeneous. Austria exempts patients from the prescription fee after reaching 2% of annual net income (fee €7.55 from 1 Jan 2026). Germany caps statutory co-payments at 2% of annual household gross income (1% for severe chronic illness). Denmark applies stepwise reimbursement with a maximum annual self-payment of DKK 4,850 for subsidized medicines. Sweden caps patient payments at SEK 3,800 per 12 months. Finland applies an annual OOP maximum for medicines (€633.17 in 2025; €636.12 in 2026) plus an annual initial deductible before reimbursement. Early/temporary access schemes illustrate alternative financing. In France, >350 early-access requests and >140,000 patients have been supported since 2021, with published scheme evaluations. Financial safeguards include annual rebates with progressive rates up to 70% by turnover bands and uplift payments linked to delays/clinical value, subject to a ceiling (e.g., total rebates ≤80% of in-scope turnover, conditional). In Belgium, new early/fast access procedures (effective 1 Jan 2026) include fixed compensation (e.g., €25,000 per accepted cohort; monthly per-patient amounts and €120,000 for cell & gene therapy) and require free-of-charge supply during interim access.
CONCLUSIONS: Across Europe, OOP caps and early/temporary financing are complementary tools to maintain affordability and manage clinical and budget uncertainty via income/annual thresholds, rebates, and time-limited compensation mechanisms.